The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.

MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327

Mortality in Randomized Trials of Antioxidant Supplements for Primary and Secondary Prevention: Systematic Review and Meta-analysis

Bjelakovic, G., Nikolova, D., Gluud, L. L., Simonetti, R. G., & Gluud, C. (2007) · JAMA · doi:10.1001/jama.297.8.842 · Cited by 2,275

Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease

Targher, G., Day, C. P., & Bonora, E. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0912063 · Cited by 1,907

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827

Vitamin E and the Risk of Prostate Cancer: The Selenium and Vitamin E Cancer Prevention Trial (SELECT)

Klein, E. A., Thompson, I. M., Tangen, C. M., Crowley, J. J., Lucia, M. S., Goodman, P. J., Minasian, L. M., Ford, L. G., Parnes, H. L., Gaziano, J. M., et al. (2011) · JAMA · doi:10.1001/jama.2011.1437 · Cited by 1,787

Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites†

Neuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077

Reversal of Nonalcoholic Hepatic Steatosis, Hepatic Insulin Resistance, and Hyperglycemia by Moderate Weight Reduction in Patients With Type 2 Diabetes

Petersen, K. F., Dufour, S., Befroy, D., Lehrke, M., Hendler, R. E., & Shulman, G. I. (2005) · Diabetes · doi:10.2337/diabetes.54.3.603 · Cited by 911

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial

Lindor, K. D., Kowdley, K. V., Heathcote, J. E., Harrison, E. M., Jorgensen, R., Angulo, P., Lymp, J. F., Burgart, L., & Colin, P. (2004) · Hepatology · doi:10.1002/hep.20092 · Cited by 727

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203

The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota

Boursier, J., Mueller, O., Barret, M., Machado, M., Fizanne, L., Araujo‐Perez, F., Guy, C. D., Seed, P. C., Rawls, J. F., David, L. A., et al. (2016) · Hepatology · doi:10.1002/hep.28356 · Cited by 1,483

Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis

Karlas, T., Petroff, D., Sasso, M., Fan, J.-G., Mi, Y.-Q., de Lédinghen, V., Kumar, M., Lupsor-Platon, M., Han, K.-H., Cardoso, A. C., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.12.022 · Cited by 1,275

Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study

Vilar-Gomez, E., Calzadilla-Bertot, L., Wai-Sun Wong, V., Castellanos, M., Aller-de la Fuente, R., Metwally, M., Eslam, M., Gonzalez-Fabian, L., Alvarez-Quiñones Sanz, M., Conde-Martin, A. F., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.04.034 · Cited by 806

Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease

Kanwal, F., Kramer, J. R., Mapakshi, S., Natarajan, Y., Chayanupatkul, M., Richardson, P. A., Li, L., Desiderio, R., Thrift, A. P., Asch, S. M., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.08.024 · Cited by 795

Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients

Lassailly, G., Caiazzo, R., Buob, D., Pigeyre, M., Verkindt, H., Labreuche, J., Raverdy, V., Leteurtre, E., Dharancy, S., Louvet, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.014 · Cited by 762

Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease

Softic, S., Cohen, D. E., & Kahn, C. R. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4054-0 · Cited by 709

ESPEN guideline on clinical nutrition in liver disease

Plauth, M., Bernal, W., Dasarathy, S., Merli, M., Plank, L. D., Schütz, T., & Bischoff, S. C. (2019) · Clinical Nutrition · doi:10.1016/j.clnu.2018.12.022 · Cited by 674

Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis

Lassailly, G., Caiazzo, R., Ntandja-Wandji, L.-C., Gnemmi, V., Baud, G., Verkindt, H., Ningarhari, M., Louvet, A., Leteurtre, E., Raverdy, V., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.06.006 · Cited by 622

The Liver as an Endocrine Organ—Linking NAFLD and Insulin Resistance

Watt, M. J., Miotto, P. M., De Nardo, W., & Montgomery, M. K. (2019) · Endocrine Reviews · doi:10.1210/er.2019-00034 · Cited by 615

Gut-liver axis, gut microbiota, and its modulation in the management of liver diseases: A review of the literature

Milosevic, I., Vujovic, A., Barac, A., Djelic, M., Korac, M., Radovanovic Spurnic, A., Gmizic, I., Stevanovic, O., Djordjevic, V., Lekic, N., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020395 · Cited by 551

Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics

Duan, Y., Gong, K., Xu, S., Zhang, F., Meng, X., & Han, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01125-5 · Cited by 538

Hispanic health in the USA: a scoping review of the literature

Velasco-Mondragon, E., Jimenez, A., Palladino-Davis, A. G., Davis, D., & Escamilla-Cejudo, J. A. (2016) · Public Health Reviews · doi:10.1186/s40985-016-0043-2 · Cited by 514

The Role of Cholesterol in the Pathogenesis of NASH

Ioannou, G. N. (2016) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2015.11.008 · Cited by 498

The role of hepatokines in metabolism

Stefan, N., & Häring, H.-U. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.258 · Cited by 500

The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease

Gadd, V. L., Skoien, R., Powell, E. E., Fagan, K. J., Winterford, C., Horsfall, L., Irvine, K., & Clouston, A. D. (2014) · Hepatology · doi:10.1002/hep.26937 · Cited by 452

Acetyl CoA carboxylase inhibition reduces hepatic steatosis but elevates plasma triglycerides in mice and humans: a bedside to bench investigation

Kim, C.-W., Addy, C., Kusunoki, J., Anderson, N. N., Deja, S., Fu, X., Burgess, S. C., Li, C., Ruddy, M., Chakravarthy, M., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.07.009 · Cited by 419

Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD

Lee, G., You, H. J., Bajaj, J. S., Joo, S. K., Yu, J., Park, S., Kang, H., Park, J. H., Kim, J. H., Lee, D. H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18754-5 · Cited by 395

Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease

Boursier, J., Vergniol, J., Guillet, A., Hiriart, J.-B., Lannes, A., Le Bail, B., Michalak, S., Chermak, F., Bertrais, S., Foucher, J., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.04.023 · Cited by 400

ESPEN practical guideline: clinical nutrition in liver disease

Bischoff, S. C., Bernal, W., Dasarathy, S., Merli, M., Plank, L. D., Schütz, T., & Plauth, M. (2020) · Clinical Nutrition · doi:10.1016/j.clnu.2020.09.001 · Cited by 383

Challenges and opportunities in NASH drug development

Harrison, S. A., Allen, A. M., Dubourg, J., Noureddin, M., & Alkhouri, N. (2023) · Nature Medicine · doi:10.1038/s41591-023-02242-6 · Cited by 353

Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action

Bril, F., & Cusi, K. (2017) · Diabetes Care · doi:10.2337/dc16-1787 · Cited by 341

Nonobese fatty liver disease

Kim, D., & Kim, W. R. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.08.028 · Cited by 341

Indications for Surgery for Obesity and Weight-Related Diseases: Position Statements from the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO)

De Luca, M., Angrisani, L., Himpens, J., Busetto, L., Scopinaro, N., Weiner, R., Sartori, A., Stier, C., Lakdawala, M., Bhasker, A. G., et al. (2016) · Obesity Surgery · doi:10.1007/s11695-016-2271-4 · Cited by 296

Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis

LI, Y., LIU, L., WANG, B., WANG, J., & CHEN, D. (2013) · Biomedical Reports · doi:10.3892/br.2012.18 · Cited by 290

Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease

Scorletti, E., Afolabi, P. R., Miles, E. A., Smith, D. E., Almehmadi, A., Alshathry, A., Childs, C. E., Del Fabbro, S., Bilson, J., Moyses, H. E., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.031 · Cited by 237

Roux-en-Y Gastric Bypass Versus Adjustable Gastric Banding to Reduce Nonalcoholic Fatty Liver Disease: A 5-Year Controlled Longitudinal Study

Caiazzo, R., Lassailly, G., Leteurtre, E., Baud, G., Verkindt, H., Raverdy, V., Buob, D., Pigeyre, M., Mathurin, P., & Pattou, F. (2014) · Annals of Surgery · doi:10.1097/sla.0000000000000945 · Cited by 226

Microbiota and Gut–Liver Axis: Their Influences on Obesity and Obesity‐Related Liver Disease

Vajro, P., Paolella, G., & Fasano, A. (2013) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e318284abb5 · Cited by 201

Vitamin E improves transplant-free survival and hepatic decompensation among patients with nonalcoholic steatohepatitis and advanced fibrosis

Vilar‐Gomez, E., Vuppalanchi, R., Gawrieh, S., Ghabril, M., Saxena, R., Cummings, O. W., & Chalasani, N. (2020) · Hepatology · doi:10.1002/hep.30368 · Cited by 193

Subclinical hypothyroidism and low-normal thyroid function are associated with nonalcoholic steatohepatitis and fibrosis

Kim, D., Kim, W., Joo, S. K., Bae, J. M., Kim, J. H., & Ahmed, A. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.08.014 · Cited by 191

Commensal microbe-derived acetate suppresses NAFLD/NASH development via hepatic FFAR2 signalling in mice

Aoki, R., Onuki, M., Hattori, K., Ito, M., Yamada, T., Kamikado, K., Kim, Y.-G., Nakamoto, N., Kimura, I., Clarke, J. M., et al. (2021) · Microbiome · doi:10.1186/s40168-021-01125-7 · Cited by 167

Beneficial effects of ginger Zingiber officinale Roscoe on obesity and metabolic syndrome: a review

Wang, J., Ke, W., Bao, R., Hu, X., & Chen, F. (2017) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13375 · Cited by 167

High Prevalence of Nonalcoholic Fatty Liver Disease in Adolescents Undergoing Bariatric Surgery

Xanthakos, S. A., Jenkins, T. M., Kleiner, D. E., Boyce, T. W., Mourya, R., Karns, R., Brandt, M. L., Harmon, C. M., Helmrath, M. A., Michalsky, M. P., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.039 · Cited by 151

Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis

Ooi, G. J., Meikle, P. J., Huynh, K., Earnest, A., Roberts, S. K., Kemp, W., Parker, B. L., Brown, W., Burton, P., & Watt, M. J. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.04.013 · Cited by 137

Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: results from a population-based study

van der Voort, E. A. M., Koehler, E. M., Dowlatshahi, E. A., Hofman, A., Stricker, B. H., Janssen, H. L. A., Schouten, J. N. L., & Nijsten, T. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.10.044 · Cited by 145

Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease

Jump, D. B., Lytle, K. A., Depner, C. M., & Tripathy, S. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.07.007 · Cited by 142

Sex-specific differences in hepatic fat oxidation and synthesis may explain the higher Propensity for NAFLD in men

Pramfalk, C., Pavlides, M., Banerjee, R., McNeil, C. A., Neubauer, S., Karpe, F., & Hodson, L. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2649 · Cited by 138

Effect of alcohol consumption on survival in nonalcoholic fatty liver disease: a national prospective cohort study

Hajifathalian, K., Torabi Sagvand, B., & McCullough, A. J. (2019) · Hepatology · doi:10.1002/hep.30226 · Cited by 128

Serum Immunoglobulin Levels Predict Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease

McPherson, S., Henderson, E., Burt, A. D., Day, C. P., & Anstee, Q. M. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.01.010 · Cited by 124

Pharmacological management of nonalcoholic fatty liver disease

Barb, D., Portillo-Sanchez, P., & Cusi, K. (2016) · Metabolism · doi:10.1016/j.metabol.2016.04.004 · Cited by 114

The role of bariatric surgery in the management of nonalcoholic fatty liver disease and metabolic syndrome

Aguilar-Olivos, N. E., Almeda-Valdes, P., Aguilar-Salinas, C. A., Uribe, M., & Méndez-Sánchez, N. (2016) · Metabolism · doi:10.1016/j.metabol.2015.09.004 · Cited by 100

Relationship between adipose tissue dysfunction, vitamin D deficiency and the pathogenesis of non-alcoholic fatty liver disease.

Cimini, F. A., Barchetta, I., Carotti, S., Bertoccini, L., Baroni, M. G., Vespasiani-Gentilucci, U., Cavallo, M.-G., & Morini, S. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i19.3407 · Cited by 101

Obesity: pathophysiology and therapeutic interventions

Kong, Y., Yang, H., Nie, R., Zhang, X., Zuo, F., Zhang, H., & Nian, X. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00264-9 · Cited by 89

Gut microbiota, fatty liver disease, and hepatocellular carcinoma

Chu, H., Williams, B., & Schnabl, B. (2018) · Liver Research · doi:10.1016/j.livres.2017.11.005 · Cited by 84

Impact of hypocaloric hyperproteic diet on gut microbiota in overweight or obese patients with nonalcoholic fatty liver disease: a pilot study

Pataky, Z., Genton, L., Spahr, L., Lazarevic, V., Terraz, S., Gaïa, N., Rubbia-Brandt, L., Golay, A., Schrenzel, J., & Pichard, C. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4179-1 · Cited by 75

Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis

Dong, Y., Lv, Q., Li, S., Wu, Y., Li, L., Li, J., Zhang, F., Sun, X., & Tong, N. (2017) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2016.11.009 · Cited by 71

Efficacy of orlistat in non‑alcoholic fatty liver disease: A systematic review and meta‑analysis

Wang, H., Wang, L., Cheng, Y., Xia, Z., Liao, Y., & Cao, J. (2018) · Biomedical Reports · doi:10.3892/br.2018.1100 · Cited by 70

Does moderate alcohol consumption accelerate the progression of liver disease in NAFLD? A systematic review and narrative synthesis

Jarvis, H., O'Keefe, H., Craig, D., Stow, D., Hanratty, B., & Anstee, Q. M. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-049767 · Cited by 71

Association between anxiety and depression and nonalcoholic fatty liver disease

Choi, J. M., Chung, G. E., Kang, S. J., Kwak, M.-S., Yang, J. I., Park, B., & Yim, J. Y. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2020.585618 · Cited by 68

Beneficial effects of mineralocorticoid receptor blockade in experimental non‐alcoholic steatohepatitis

Pizarro, M., Solís, N., Quintero, P., Barrera, F., Cabrera, D., Rojas‐de Santiago, P., Arab, J. P., Padilla, O., Roa, J. C., Moshage, H., et al. (2015) · Liver International · doi:10.1111/liv.12794 · Cited by 66

DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases

Handelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Beckman, J. A., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., et al. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.108101 · Cited by 64

Health-related quality of life burden of nonalcoholic steatohepatitis: a robust pragmatic literature review

Kennedy-Martin, T., Bae, J. P., Paczkowski, R., & Freeman, E. (2018) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-018-0052-7 · Cited by 61

Endoscopic duodenal mucosal resurfacing improves glycaemic and hepatic indices in type 2 diabetes: 6-month multicentre results

van Baar, A. C. G., Beuers, U., Wong, K., Haidry, R., Costamagna, G., Hafedi, A., Deviere, J., Ghosh, S. S., Lopez-Talavera, J. C., Rodriguez, L., et al. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.10.006 · Cited by 55

DSS colitis promotes tumorigenesis and fibrogenesis in a choline-deficient high-fat diet-induced NASH mouse model

Achiwa, K., Ishigami, M., Ishizu, Y., Kuzuya, T., Honda, T., Hayashi, K., Hirooka, Y., Katano, Y., & Goto, H. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.12.012 · Cited by 54

Insulin Regulation of Hepatic Lipid Homeostasis

Uehara, K., Santoleri, D., Whitlock, A. E. G., & Titchenell, P. M. (2023) · Comprehensive Physiology · doi:10.1002/cphy.c220015 · Cited by 49

GLP‐1 receptor agonists: effects on the progression of non‐alcoholic fatty liver disease

Liu, J., Wang, G., Jia, Y., & Xu, Y. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2580 · Cited by 48

Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease?

Mazzotti, A., Caletti, M. T., Marchignoli, F., Forlani, G., & Marchesini, G. (2017) · Digestive and Liver Disease · doi:10.1016/j.dld.2016.12.028 · Cited by 46

Docosahexaenoic acid attenuates Western diet-induced hepatic fibrosis in Ldlr mice by targeting the TGFβ-Smad3 pathway

Lytle, K. A., Depner, C. M., Wong, C. P., & Jump, D. B. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m061275 · Cited by 45

Rapid response of the steatosis-sensing hepatokine LECT2 during diet-induced weight cycling in mice

Chikamoto, K., Misu, H., Takayama, H., Kikuchi, A., Ishii, K.-A., Lan, F., Takata, N., Tajima-Shirasaki, N., Takeshita, Y., Tsugane, H., et al. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.08.117 · Cited by 37

Performance of American Gastroenterological Association Clinical Care Pathway for the risk stratification of patients with nonalcoholic fatty liver disease in the US population

Udompap, P., Therneau, T. M., Canning, R. E., Benson, J. T., & Allen, A. M. (2023) · Hepatology · doi:10.1002/hep.32739 · Cited by 37

Loss of progesterone receptor membrane component 1 promotes hepatic steatosis via the induced de novo lipogenesis

Lee, S. R., Kwon, S. W., Kaya, P., Lee, Y. H., Lee, J. G., Kim, G., Lee, G.-S., Baek, I.-J., & Hong, E.-J. (2018) · Scientific Reports · doi:10.1038/s41598-018-34148-6 · Cited by 37

Picroside II attenuates fatty acid accumulation in HepG2 cells via modulation of fatty acid uptake and synthesis

Dhami-Shah, H., Vaidya, R., Udipi, S., Raghavan, S., Abhijit, S., Mohan, V., Balasubramanyam, M., & Vaidya, A. (2018) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2017.0039 · Cited by 36

Endoscopic Sleeve Gastroplasty Plus Lifestyle Intervention in Patients With Metabolic Dysfunction-associated Steatohepatitis: A Multicenter, Sham-controlled, Randomized Trial

Abad, J., Llop, E., Arias-Loste, M. T., Burgos-Santamaría, D., Martínez Porras, J. L., Iruzubieta, P., Graus, J., Ruiz-Antorán, B., Sánchez Yuste, M. R., Romero-Gómez, M., et al. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.10.027 · Cited by 35

Circulating adiponectin levels in type 2 diabetes mellitus patients with or without non-alcoholic fatty liver disease: Results of a small, open-label, randomized controlled intervention trial in a subgroup receiving short-term exenatide

Savvidou, S., Karatzidou, K., Tsakiri, K., Gagalis, A., Hytiroglou, P., & Goulis, J. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.12.003 · Cited by 30

Electron microscopic observations in perfusion-fixed human non-alcoholic fatty liver disease biopsies

Verhaegh, P., Wisse, E., de Munck, T., Greve, J. W., Verheij, J., Riedl, R., Duimel, H., Masclee, A., Jonkers, D., & Koek, G. (2021) · Pathology · doi:10.1016/j.pathol.2020.07.018 · Cited by 22

Hepatic Steatosis in Patients with Celiac Disease: The Role of Packaged Gluten-Free Foods

Raiteri, A., Granito, A., Faggiano, C., Giamperoli, A., Catenaro, T., Negrini, G., & Tovoli, F. (2022) · Nutrients · doi:10.3390/nu14142942 · Cited by 20

Association of non-alcoholic fatty liver disease with self-reported osteoarthritis among the US adults

Lu, Y., Zhang, J., Li, H., & Li, T. (2024) · Arthritis Research & Therapy · doi:10.1186/s13075-024-03272-2 · Cited by 19

The PNPLA3 I148M variant is associated with transaminase elevations in type 2 diabetes patients treated with basal insulin peglispro

Pillai, S., Duvvuru, S., Bhatnagar, P., Foster, W., Farmen, M., Shankar, S., Harris, C., Bastyr, E., Hoogwerf, B., & Haupt, A. (2018) · The Pharmacogenomics Journal · doi:10.1038/tpj.2017.45 · Cited by 19

Inhibition of microRNA-33b in humanized mice ameliorates nonalcoholic steatohepatitis

Miyagawa, S., Horie, T., Nishino, T., Koyama, S., Watanabe, T., Baba, O., Yamasaki, T., Sowa, N., Otani, C., Matsushita, K., et al. (2023) · Life Science Alliance · doi:10.26508/lsa.202301902 · Cited by 14

Resmetirom: A Systematic Review of the Revolutionizing Approach to Non-alcoholic Steatohepatitis Treatment Focusing on Efficacy, Safety, Cost-Effectiveness, and Impact on Quality of Life

Bittla, P., Paidimarri, S. P., Ayuthu, S., Chauhan, Y. D., Saad, M. Z., Mirza, A. A., & Khan, S. (2024) · Cureus · doi:10.7759/cureus.69919 · Cited by 11

A preliminary study of associating liver partition and portal vein ligation for staged hepatectomy in a rat model of liver cirrhosis

Yang, X., Yang, C., Qiu, Y., Shen, S., Kong, J., & Wang, W. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7688 · Cited by 6